NASDAQ:EVAX Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis $2.43 +0.13 (+5.65%) Closing price 05/30/2025 03:55 PM EasternExtended Trading$2.67 +0.24 (+9.88%) As of 05/30/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evaxion Biotech A/S Stock (NASDAQ:EVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evaxion Biotech A/S alerts:Sign Up Key Stats Today's Range$2.31▼$2.4850-Day Range$1.31▼$2.6352-Week Range$1.20▼$19.95Volume65,133 shsAverage Volume611,628 shsMarket Capitalization$3.41 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Read More… Evaxion Biotech A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreEVAX MarketRank™: Evaxion Biotech A/S scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvaxion Biotech A/S has only been the subject of 1 research reports in the past 90 days.Read more about Evaxion Biotech A/S's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Evaxion Biotech A/S are expected to decrease in the coming year, from ($0.15) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion Biotech A/S is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion Biotech A/S is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evaxion Biotech A/S's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.07% of the float of Evaxion Biotech A/S has been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently decreased by 34.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvaxion Biotech A/S does not currently pay a dividend.Dividend GrowthEvaxion Biotech A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.07% of the float of Evaxion Biotech A/S has been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently decreased by 34.95%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.32 News SentimentEvaxion Biotech A/S has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Evaxion Biotech A/S this week, compared to 2 articles on an average week.Search Interest4 people have searched for EVAX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.04% of the stock of Evaxion Biotech A/S is held by institutions.Read more about Evaxion Biotech A/S's insider trading history. Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address EVAX Stock News HeadlinesZacks Small Cap Issues Negative Estimate for EVAX EarningsMay 31 at 1:31 AM | americanbankingnews.comEvaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call TranscriptMay 29 at 10:30 PM | msn.comThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.June 1, 2025 | True Market Insiders (Ad)Evaxion Biotech’s Earnings Call Highlights Progress and ChallengesMay 29 at 10:30 PM | msn.comEvaxion Biotech Reports Q1 2025 Progress and FinancialsMay 28, 2025 | tipranks.comEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptMay 27, 2025 | seekingalpha.comEvaxion Biotech: Evaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | finanznachrichten.deEvaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | globenewswire.comSee More Headlines EVAX Stock Analysis - Frequently Asked Questions How have EVAX shares performed this year? Evaxion Biotech A/S's stock was trading at $4.2270 on January 1st, 2025. Since then, EVAX shares have decreased by 42.5% and is now trading at $2.43. View the best growth stocks for 2025 here. How were Evaxion Biotech A/S's earnings last quarter? Evaxion Biotech A/S (NASDAQ:EVAX) released its earnings results on Tuesday, May, 27th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.36. Read the conference call transcript. When did Evaxion Biotech A/S's stock split? Evaxion Biotech A/S's stock reverse split on Monday, January 13th 2025. The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did Evaxion Biotech A/S IPO? Evaxion Biotech A/S (EVAX) raised $31 million in an IPO on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager. Who are Evaxion Biotech A/S's major shareholders? Evaxion Biotech A/S's top institutional investors include Merck & Co. Inc. (86.54%) and XTX Topco Ltd (1.16%). How do I buy shares of Evaxion Biotech A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evaxion Biotech A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion Biotech A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML). Company Calendar Last Earnings5/27/2025Today6/01/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVAX CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$14.00 Low Stock Price Target$6.00 Potential Upside/Downside+311.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.12 million Net Margins-347.83% Pretax Margin-368.80% Return on EquityN/A Return on Assets-79.40% Debt Debt-to-Equity Ratio7.99 Current Ratio1.00 Quick Ratio2.80 Sales & Book Value Annual Sales$3.29 million Price / Sales1.04 Cash FlowN/A Price / Cash FlowN/A Book Value($5.83) per share Price / Book-0.42Miscellaneous Outstanding Shares1,403,000Free Float685,000Market Cap$3.41 million OptionableNo Data Beta-0.24 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:EVAX) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion Biotech A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.